| Business Summary | | Thoratec
Corporation
develops,
manufactures
and
markets
proprietary
medical
devices
used
for
circulatory
support,
vascular
graft,
blood
coagulation
and
skin
incision
applications.
The
Company
markets
the
Thoratec
Ventricular
Assist
Device
System
(Thoratec
VAD
System)
and
the
HeartMate
Left
Ventricular
Assist
System
(the
HeartMate
LVAS)
for
use
as
a
bridge
to
heart
transplant.
Additionally,
the
Thoratec
VAD
System
is
marketed
for
use
in
the
recovery
of
the
heart
after
open-heart
surgery,
and
the
HeartMate
LVAS
is
marketed
internationally
as
an
alternative
to
medical
therapy.
The
Company
has
also
developed
small
diameter
vascular
grafts
for
use
in
hemodialysis
access
and
coronary
artery
bypass
surgery.
All
of
these
products
that
come
into
contact
with
human
tissue
or
blood
incorporate
Thoralon,
a
proprietary
biomaterial
that
provides
strength
and
flexibility
to
its
products,
with
surface
properties
designed
to
minimize
patient
blood
clotting
and
inflammatory
response. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Thoratec
is
engaged
in
the
research,
development,
manufacturing
and
marketing
of
medical
devices
for
circulatory
support,
vascular
graft,
blood
coagulation
and
skin
incision
applications.
For
the
six
months
ended
6/30/01,
revenues
rose
17%
to
$49.7
million.
Net
loss
before
extraordinary
item
totaled
$85.3
million
vs.
an
income
of
$4.2
million.
Revenues
reflect
the
merger.
Net
loss
reflects
$76.9
million
in
acquired
in-process
R&D
expenses
and
$6.8
million
in
goodwill
amortization. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| J. Donald Hill, 64 Chairman | -- | -- | D. Keith Grossman, 40 Pres,
CEO, Director | $470K | -- | M. Wayne Bolyston, 43 CFO,
Sr. VP | -- | -- | Thomas Burnett, Jr., 37 COO,
Sr. VP | 336K | $158K | Jeffrey Mack, 38 VP-Fin.,
Controller | -- | -- | Dollar
amounts are as of 30-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|